# HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

> **NCT01147848** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 810 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone furoate/Vilanterol Inhalation Powder
- **DRUG:** Fluticasone propionate/salmeterol Inhalation Powder
- **DRUG:** Placebo (1)
- **DRUG:** Placebo (2)

## Key facts

- **NCT ID:** NCT01147848
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 810 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147848, "HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01147848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*